What Makes an Antipsychotic Atypical?
J Clin Psychiatry 1998;59:403-404
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
A flood of new antipsychotics is generating improved treatments for schizophrenia but tangled terminology for clinicians. All of the newer antipsychotics since clozapine have been lumped into a new therapeutic class often referred to as “atypical” (This includes not only risperidone, olanzapine, and quetiapine, but also sertindole (marketed only outside the United States) and ziprasidone (expected to be approved in the United States soon). Lumping all of the new agents together helps to distinguish them as a class from most of the older conventional antipsychotics, which are clearly less tolerated and possibly less effective, especially for negative symptoms. These new agents must distinguish themselves from the older generic agents if they hope to support price premiums.